Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia

Journal of Medical Economics

Volumn 11, Issue 4, 2008, Pages 651-670

  Ali, Mohammed ^a   White, Jeremy ^b   Lee, Chen Hui ^b   Palmer, James L ^a   Smith Palmer, Jayne ^a   Fakhoury, Walid ^a   Valentine, William J ^a  

^a IQVIA   (United States)

^b Novo Nordisk FemCare AG   (Switzerland)

Author keywords

Cost effectiveness; Diabetes; Insulin; Modelling; Saudi Arabia

Indexed keywords

ACETYLSALICYLIC ACID; BIPHASIC INSULIN; BIPHASIC INSULIN ASPART 30; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HUMAN INSULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN ASPART; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN, ASP(B28)-;

ADULT; ARTICLE; CLINICAL TRIAL; COMORBIDITY; COMPUTER SIMULATION; CONTROLLED STUDY; COST CONTROL; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; SAUDI ARABIA; DIABETES MELLITUS; ECONOMICS; GLYCEMIC INDEX; MIDDLE AGED; OUTCOME ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; COMPUTER SIMULATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GLYCEMIC INDEX; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIFE EXPECTANCY; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SAUDI ARABIA; SENSITIVITY AND SPECIFICITY;

EID: 67449087012     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802589122     Document Type: Article

References (40)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998: 21(9): 1414-1431.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004: 27(5): 1047-1053.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006: 3(11): e442
4. Bacchus RA, Bell JL, Madkour M, Kilshaw B. The prevalence of diabetes mellitus in male Saudi Arabs. Diabetologia 1982: 23(4): 330-332.
5. Fatani HH, Mira SA, el-Zubier AG. Prevalence of diabetes mellitus in rural Saudi Arabia. Diabetes Care 1987: 10(2): 180-183.
6. El-Hazmi MA, Warsy AS, Al-Swailem AR et al. Diabetes mellitus and impaired glucose tolerance in Saudi Arabia. Annals of Saudi Medicine 1996: 16(4): 381-385. (Pubitemid 26293608)
7. Al-Nuaim AR. Prevalence of glucose intolerance in urban and rural communities in Saudi Arabia. Diabetic Medicine 1997: 14(7): 595-602. (Pubitemid 27298821)
8. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY et al. Diabetes mellitus in Saudi Arabia. Saudi Medical Journal 2004: 25(11): 1603-1610. (Pubitemid 39646631)
9. El-Hazmi MA, Al-Swailem AR, Warsy AS et al. Consanguinity among the Saudi Arabian population. Journal of Medical Genetics 1995: 32(8): 623-626.
10. Anokute CC. Suspected synergism between consanguinity and familial aggregation in type 2 diabetes mellitus in Saudi Arabia. Journal of the Royal Society for the Promotion of Health 1992: 112(4): 167-169.
11. Diabetes Atlas, 2nd edn. Brussels: International Diabetes Federation; 2003.
12. Khutsoane D, Sharma SK, Almustafa M et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes, Obesity and Metababolism 2008: 103: 212-222. (Pubitemid 351247337)
13. Sharma SK, Al-Mustafa M, Oh SJ et al. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Current Medical Research and Opinion 2008: 24(3): 645-652.
14. Alghasham AA, Barakat YA. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi Medical Journal 2008: 29(2): 185-192.
15. Palmer AJ, Roze S, Valentine WJ et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus(types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004: 20(Suppl 1): 5-26. (Pubitemid 39349905)
16. D'Agostino RB, Russell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. American Heart Journal 2000: 139(2 Pt 1): 272-281. (Pubitemid 30090804)
17. Palmer AJ, Roze S, Valentine W et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Current Medical Research and Opinion 2004: 20(Suppl 1): S27-S40. (Pubitemid 39349906)
18. World Health Organization. Life tables for 191 countries. World mortality in 2005. Available at: http://www3.who.int/whosis/life-tables/life-tables.cfm Accessed May 2008
19. World Health Organization. Global Burden of Disease Estimates. Available at: http://www.who.int/healthinfo/bodestimates/en/index.html Accessed May 2008
20. Al Wakeel JS, Mitwalli AH, Al MS et al. Morbidity and mortality in ESRD patients on dialysis. Saudi Journal of Kidney Diseases and Transplantation 2002: 13(4): 473-477. (Pubitemid 36111066)
21. Shaheen FA, Basri N, Mohammed Z et al. Experience of renal transplantation at the King Fahd Hospital, Jeddah, Saudi Arabia. Saudi Journal of Kidney Diseases and Transplantation 2005: 16(4): 562-572. (Pubitemid 43123432)
22. Shestakova M, Bech OM, Momani MS. Study design and baseline characteristics of patients in the PRESENT study. Diabetes Research and Clinical Practice 2008: 81(Suppl 1): S3-S9.
23. UK Prospective Diabetes Study(UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-853.
24. Al-Daghri NM, Al-Attas OS, Al-Rubeaan K. The atherogenic and metabolic impact of non-HDL cholesterol versus other lipid sub-components among non-diabetic and diabetic Saudis. Lipids in Health and Disease 2007: 6: 9. (Pubitemid 46666815)
25. Nielsen JV. Peripheral neuropathy, hypertension, foot ulcers and amputations among Saudi Arabian patients with type 2 diabetes. Diabetes Research and Clinical Practice 1998: 41(1): 63-69. (Pubitemid 28394286)
26. Abu-Amero KK, Al-Boudari OM, Mohamed GH, Dzimiri N. Beta 3 adrenergic receptor Trp64Arg polymorphism and manifestation of coronary artery disease in Arabs. Human Biology 2005: 77(6): 795-802. (Pubitemid 43727748)
27. Valentine WJ, Palmer AJ, Nicklasson L et al. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. International Journal of Clinical Practice 2006: 60(9): 1138-1145. (Pubitemid 44226756)
28. Elhadd TA, Al-Amoudi AA, Alzahrani AS. Epidemiology, clinical and complications profile of diabetes in Saudi Arabia: a review. Annals of Saudi Medicine 2007: 27(4): 241-250. (Pubitemid 47527590)
29. Currie CJ, Morgan CL, Poole CD et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion 2006; 22(8): 1523-1534. (Pubitemid 44297431)
30. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
31. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics 1997: 6(4): 327-340. (Pubitemid 27384638)
32. Kothari V, Stevens RJ, Adler AI et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002: 33(7): 1776-1781. (Pubitemid 34761059)
33. Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006: 19(2): CD003287. (Pubitemid 46841364)
34. El-Asrar AM, Al-Rubeaan KA, Al-Amro SA et al. Risk factors for diabetic retinopathy among Saudi diabetics. International Ophthalmology 1998: 22(3): 155-161
35. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002: 45(7): S13-S17. (Pubitemid 34762209)
36. Al-Maskari F, El-Sadig M, Obineche E. Prevalence and determinants of microalbuminuria among diabetic patients in the United Arab Emirates. BMC Nephrology 2008: 9: 1.
37. Shaheen FA, Al-Khader AA. Preventive strategies of renal failure in the Arab world. Kidney International Supplement 2005: 98: S37-S40. (Pubitemid 43307847)
38. King Saud University. The cost of diabetes in the kingdom of Saudi Arabia. Available at: http://www.sgh.org.sa/Diabetes-Conf/Day%202/Session%202/ DM%20cost.pdf. Accessed December 2008.
39. Al-Wahbi AM. The diabetic foot. In the Arab world. Saudi Medical Journal 2006: 27(2): 147-153.
40. McGill MJ, Donnelly R, Molyneaux L, Yue DK. Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM. Diabetes Research and Clinical Practice 1996: 33(3): 173-179. (Pubitemid 26371606)